Rilemo’s commercial model is designed to combine upfront device sales with recurring software and service revenues, creating both initial hardware value capture and a growing installed-base revenue stream over time.
Rilemo is being developed as a portable low-power microwave neuro-imaging device designed to provide rapid point-of-care anatomical information in cerebrovascular care settings, complementing standard imaging modalities such as CT and MRI.
This positioning supports a business model and pricing logic closer to an accessible portable neuro-imaging platform than to standard bedside monitors or non-imaging neuro-triage tools.
Rilemo’s value proposition is grounded in its ability to bring brain imaging-derived information closer to the patient, in settings where access to conventional imaging may be delayed, logistically complex, or less compatible with unstable patients.
In this context, the platform is designed to create value through:
Beyond its direct clinical value, Rilemo may also contribute to a more efficient use of existing imaging infrastructure. By providing earlier bedside support, the platform can help reduce pressure on urgent CT and MRI workflows, improve the prioritization of available imaging capacity, and enhance the overall utilization of high-cost diagnostic resources.
From an economic perspective, the main value drivers of a portable neuro-imaging platform include fewer repeat CT/MRI scans, reduced inter-hospital transfers of unstable patients, and shorter ICU or high-dependency stays. In this context, conventional imaging exams may already represent several hundred EUR/USD per scan, while ICU daily costs in European settings are often in the order of ~€1,200-2,000 per day. Based on analogous technologies and pathway-level assumptions, this makes it plausible for mid-volume sites to recover the investment in a mid-five-figure to low-six-figure system within roughly two years, provided that the device delivers measurable improvements in their clinical workflow and decision pathway.
Rilemo is positioned between baseline bedside tools and advanced portable and mobile neuro-imaging systems.
At the lower end of the benchmark sit non-imaging neuro-triage tools, ICU monitoring platforms, and high-spec portable ultrasound systems, which typically range in the mid-five-figure range but do not provide dedicated brain imaging.
At the upper end sit portable neuro-imaging and mobile imaging solutions, such as portable MRI, mobile CT, and stroke-unit-based imaging systems, which command significantly higher pricing and operational complexity.